eprintid: 10078071
rev_number: 20
eprint_status: archive
userid: 608
dir: disk0/10/07/80/71
datestamp: 2019-07-16 10:03:32
lastmod: 2021-11-15 03:32:18
status_changed: 2019-07-16 10:03:32
type: article
metadata_visibility: show
creators_name: D'Haens, G
creators_name: Rieder, F
creators_name: Feagan, BG
creators_name: Higgins, PDR
creators_name: Panes, J
creators_name: Maaser, C
creators_name: Rogler, G
creators_name: Löwenberg, M
creators_name: van der Voort, R
creators_name: Pinzani, M
creators_name: Peyrin-Biroulet, L
creators_name: Danese, S
creators_name: IOIBD Fibrosis Working Group, .
title: Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease
ispublished: inpress
divisions: UCL
divisions: B02
divisions: C10
divisions: D17
divisions: G91
note: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
abstract: Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) that is usually the consequence of chronic inflammation. Although the currently available anti-inflammatory therapies have had little impact on intestinal fibrosis in Crohn’s disease (CD), increased understanding of the pathophysiology and the development of therapies targeting fibrogenic pathways hold promise for the future. One of the critical challenges is how reduction or reversal of intestinal fibrosis should be defined and measured in the setting of clinical trials and drug approval. The International Organization for Inflammatory Bowel Disease (IOIBD) organized a workshop in Amsterdam, The Netherlands, on December 19th and 20th, 2018 in an attempt to review the current knowledge of the biological background, diagnosis, treatment of intestinal fibrosis and clinical trial endpoints. Basic and clinical scientists discussed the pathophysiology of intestinal fibrosis, the current status of biomarkers and imaging modalities in stenosing CD, and recent clinical studies in this area. Researchers from outside of the IBD field presented advances in the understanding of fibrotic processes in other organs, such as the skin, liver and lungs. Lastly, the design of clinical trials with antifibrotic therapy for IBD was discussed, with priority on patient populations, patient reported outcomes (PROs) and imaging. This report summarizes the key findings, discussions and conclusions of the workshop.
date: 2019-06-27
date_type: published
official_url: https://doi.org/10.1053/j.gastro.2019.05.072
oa_status: green
full_text_type: other
language: eng
primo: open
primo_central: open_green
article_type_text: Journal Article
verified: verified_manual
elements_id: 1672593
doi: 10.1053/j.gastro.2019.05.072
pii: S0016-5085(19)41035-4
language_elements: English
lyricists_name: Pinzani, Massimo
lyricists_id: MPINZ74
actors_name: Flynn, Bernadette
actors_id: BFFLY94
actors_role: owner
full_text_status: public
publication: Gastroenterology
event_location: United States
issn: 0016-5085
citation:        D'Haens, G;    Rieder, F;    Feagan, BG;    Higgins, PDR;    Panes, J;    Maaser, C;    Rogler, G;                         ... IOIBD Fibrosis Working Group, .; + view all <#>        D'Haens, G;  Rieder, F;  Feagan, BG;  Higgins, PDR;  Panes, J;  Maaser, C;  Rogler, G;  Löwenberg, M;  van der Voort, R;  Pinzani, M;  Peyrin-Biroulet, L;  Danese, S;  IOIBD Fibrosis Working Group, .;   - view fewer <#>    (2019)    Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease.                   Gastroenterology        10.1053/j.gastro.2019.05.072 <https://doi.org/10.1053/j.gastro.2019.05.072>.    (In press).    Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10078071/7/Pinzani_Challenges%20in%20the%20Pathophysiology%2C%20Diagnosis%20and%20Management%20of%20Intestinal%20Fibrosis%20in%20Inflammatory%20Bowel%20Disease_AAM.pdf